Inhalation by design: Dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD

This paper describes the successful design and development of dual pharmacology β-2 agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using the principles of ‘inhalation by design’. A key feature of this work is the combination of balanced potency and pharmacodynam...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Bioorganic & medicinal chemistry letters Ročník 21; číslo 9; s. 2759 - 2763
Hlavní autoři: Jones, Lyn H., Baldock, Helen, Bunnage, Mark E., Burrows, Jane, Clarke, Nick, Coghlan, Michele, Entwistle, David, Fairman, David, Feeder, Neil, Fulton, Craig, Hilton, Laura, James, Kim, Jones, Rhys M., Kenyon, Amy S., Marshall, Stuart, Newman, Sandra D., Osborne, Rachel, Patel, Sheena, Selby, Matthew D., Stuart, Emilio F., Trevethick, Michael A., Wright, Karen N., Price, David A.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Amsterdam Elsevier Ltd 01.05.2011
Elsevier
Témata:
ISSN:0960-894X, 1464-3405, 1464-3405
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:This paper describes the successful design and development of dual pharmacology β-2 agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using the principles of ‘inhalation by design’. A key feature of this work is the combination of balanced potency and pharmacodynamic duration with desirable pharmacokinetic and material properties, whilst keeping synthetic complexity to a minimum.
Bibliografie:http://dx.doi.org/10.1016/j.bmcl.2010.10.132
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0960-894X
1464-3405
1464-3405
DOI:10.1016/j.bmcl.2010.10.132